title: Infectious complications after allogeneic stem cell transplantation: incidence in matched-related and matched-unrelated transplant settings.
abstract: BACKGROUND
  Bacterial, viral, and fungal pathogens frequently cause severe, life-threatening infections in immunocompromised patients after allogeneic hematopoietic stem cell transplantation (SCT).
  
  
  OBJECTIVE
  To compare the frequency of infections in patients with matched-related (Group A) or with human leukocyte antigen (HLA)-matched-unrelated donors (Group B).
  
  
  METHODS
  Patients treated at our transplantation unit between April 2004 and April 2005 were enrolled into this analysis. Documentation comprised demographic data, conditioning treatment, stem cell source, clinical course, as well as microbiological and clinical data and mortality.
  
  
  RESULTS
  We analyzed 59 patients, 22 in Group A and 37 in Group B. Both groups were well balanced regarding demographic data. Diagnoses were acute myeloid leukemia (30 of 59 patients, 50.8%), multiple myeloma (15.2%), acute lymphoblastic leukemia (11.9%), and chronic myeloid leukemia (10.2%). Patients in Group A developed infections in 95.5% of the cases compared with 97.3% in patients in Group B. Most frequently detected pathogens were Staphylococcus species, human herpesvirus-6, and Epstein-Barr virus. Three proven fungal infections were detected in Group A compared with 9 proven fungal infections in Group B. Lung infiltrations were observed in equivalent incidence in both groups. Two years after transplantation, 55.9% of patients were alive (Group A: 68.2%; Group B: 48.6%, not significant).
  
  
  CONCLUSIONS
  Allogeneic SCT from HLA-matched-unrelated donors does not have a higher infection risk than patients transplanted from matched-related donors.
authors.affiliation: Department of Hematology/Oncology, University of Munich Campus Grosshadern, Munich, Germany. christina.rieger@med.uni-muenchen.de
authors.forename: C T
authors.initials: CT
authors.lastname: Rieger
authors.forename: H
authors.initials: H
authors.lastname: Rieger
authors.forename: H J
authors.initials: HJ
authors.lastname: Kolb
authors.forename: L
authors.initials: L
authors.lastname: Peterson
authors.forename: S
authors.initials: S
authors.lastname: Huppmann
authors.forename: M
authors.initials: M
authors.lastname: Fiegl
authors.forename: H
authors.initials: H
authors.lastname: Ostermann
mesh_terms: D000328:Adult; D001424:Bacterial Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D046148:Donor Selection; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D018570:Risk Assessment; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*; D014777:Virus Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology